Clinical trial
A Study of ASP1951 in Subjects With Advanced Solid Tumors
NCT03799003
Study timeline
Study start (actual)2019-01-14Date precision: day
Registry last updated2024-11-01
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Advanced Solid Tumorsunresolved
Interventions
ASP1951DRUG
pembrolizumabDRUG · verified · RxNorm: pembrolizumab
Sponsors & collaborators
Astellas Pharma Global Development, Inc.lead sponsor
Merck Sharp & Dohme LLCcollaborator
Mapped research locations
SeoulSouth Korea4New YorkNew York, United States2ChicagoIllinois, United States2AtlantaGeorgia, United States1San AntonioTexas, United States1DurhamNorth Carolina, United States1DetroitMichigan, United States1TaipeiTaiwan1OmahaNebraska, United States1Salt Lake CityUtah, United States1Las VegasNevada, United States1CharlestonSouth Carolina, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03799003 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.